TuHURA Biosciences, Inc./NV Business Summary

TuHURA Biosciences, Inc. (HURA) is a Phase 3 registration-stage immuno-oncology company that operates on a clinical-stage biotechnology business model, currently generating value through the advancement of its proprietary pipeline rather than commercial product sales. The company focuses on overcoming primary and acquired resistance to cancer immunotherapies, with its primary business segments divided into personalized cancer vaccines, VISTA-blocking immunotherapies, and bi-functional antibody-drug conjugates (ADCs). Its lead candidate, IFx-2.0, is an innate immune agonist currently in a Phase 3 trial as an adjunctive therapy to Keytruda for Merkel Cell Carcinoma. TuHURA competes with other small-cap medical and biotech firms such as Milestone Pharmaceuticals, Century Therapeutics, and Caribou Biosciences, positioning itself as a specialized late-stage player focused specifically on the tumor microenvironment and checkpoint inhibitor resistance. The company is led by President and CEO Dr. James A. Bianco, a 30-year industry veteran who previously founded CTI Biopharma and oversaw multiple FDA drug approvals. The founding scientific team includes Dr. Michael Lawman and Dr. Patricia Lawman, who established the core technology platforms. Key executive leadership also includes Dan Dearborn as CFO and Dr. Bertrand Le Bourdonnec as Executive VP of Drug Discovery. TuHURA’s board of directors features high-profile industry figures, including Chairman Dr. James S. Manuso and Dr. Craig L. Tendler, the former Vice President of Oncology Clinical Development at Johnson & Johnson. Following its 2024 merger with Kintara Therapeutics and the 2025 acquisition of Kineta’s VISTA assets, the company has secured significant institutional backing and equity financing to fund its registrational trials through 2026.